Thomson Reuters Corp. Stock Rises Thursday, Outperforms Market
Dow Jones2026/10/08 20:36This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Thomson Reuters Corp. TRI rose 1.90% to C$144.46 Thursday, in what proved to be an all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.30% to 35,145.38. Thomson Reuters Corp. closed 37.2% below its 52-week high of C$230.00, which the company reached on October 24th. Trading volume of 577,859 shares remained below its 50-day average volume of 685,784. Data source: Dow Jones Market Data, FactSet. Data compiled October 8, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires October 08, 2026 16:36 ET (20:36 GMT)
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Thomson Reuters Corp. TRI rose 1.90% to C$144.46 Thursday, in what proved to be an all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.30% to 35,145.38.
Thomson Reuters Corp. closed 37.2% below its 52-week high of C$230.00, which the company reached on October 24th.
Trading volume of 577,859 shares remained below its 50-day average volume of 685,784.
Data source: Dow Jones Market Data, FactSet. Data compiled October 8, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 08, 2026 16:36 ET (20:36 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
